Ivey Business School (Canada)
-
SIGA Technologies: Profiting From Uncertainty
Mehmet A. Begen; Can CuiCase IVEY-9B11E014-ECorporate GovernanceAn equity analyst at Nova Funds, an investment firm, is in the process of analyzing an investment in SIGA Technologies (SIGA), and potentially its competitor, PharmAthene Inc. (PIP). SIGA is currently the only company in the world that has developed a treatment for smallpox, with its ST-246. In late 2010, the U.S. Department of Health and Human Services (HHS) announced the intention to award SIGA a contract valued at up to $2.8 billion, which sig...Starting at €8.20